1887

Abstract

Nineteen yeast colonies secreting rabies virus glycoprotein (G) peptides immunoreactive with polyclonal anti-rabies virus sera were selected from a random expression library. The peptides, around 80 amino acids long, spanned amino acids 54–494 of the G protein. These peptides, together with two constructions including, respectively, immunodominant sites II and III, were analysed for their immunoreactivity with 40 anti-G protein monoclonal antibodies (MAbs) composed of 12 MAbs that reacted with SDS-treated protein in Western blot under reducing conditions (WB) and 28 representative MAbs that did not react after denaturation (WB). This last category represents 98% of anti-rabies virus G MAbs. None of the WB MAbs bound peptides. Of the 12 WB MAbs, one bound two peptides situated before the transmembrane domain of the protein and six bound peptides overlapping a region situated between amino acids 223 and 276. These six MAbs define a new antigenic region that would be considered ‘immunodominant’ if the peptide strategy had been used to study the antigenicity of the protein; however, this region is only recognized by about 1% of our MAbs. Three of these WB MAbs had significant neutralizing activity; two were used for the selection of antigenic mutants (MAR mutants). Some mutants had a substitution within the region delimited by the peptides, confirming the pertinence of both the peptide and escape mutant approaches. However, a few mutants had a substitution outside the peptide-delimited region, suggesting that remote mutation(s) could affect epitope accessibility in the native protein.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-77-2-339
1996-02-01
2022-05-20
Loading full text...

Full text loading...

/deliver/fulltext/jgv/77/2/JV0770020339.html?itemId=/content/journal/jgv/10.1099/0022-1317-77-2-339&mimeType=html&fmt=ahah

References

  1. Benichou S., Legrand R., Nakagawa N., Faure T., Traincard F., Vogt G., Dormont D., Tiollais P., Kieny M. P., Madaule P. 1992; Identification of a neutralizing domain in the external envelope glycoprotein of simian immunodeficiency virus. AIDS Research and Human Retroviruses 8:1165–1170
    [Google Scholar]
  2. Benmansour A., Leblois H., Coulon P., Tufferau C., Gaudin Y., Flamand A., Lafay F. 1991; Antigenicity of rabies glycoprotein. Journal of Virology 65:4198–4203
    [Google Scholar]
  3. Benmansour A., Brahimi M., Tuffereau C., Coulon P., Lafay F., Flamand A. 1992; Rapid sequence evolution of street rabies glycoprotein is related to the highly heterogeneous nature of viral population. Virology 187:33–45
    [Google Scholar]
  4. Brake A. J., Merryweather J. P., Coit D. G., Heberlein U. A., Masiarz F. R., Mullenbach G. T., Urdea M. S., Valenzuela P., Barr P. J. 1984; α-Factor directed synthesis and secretion of mature foreign proteins in S. cerevisiae . Proceedings of the National Academy of Sciences, USA 82:7086–7090
    [Google Scholar]
  5. Bunschoten F. L., Gore I. J. T. M., Claassen M., Uytdehaag F. G. C. M., Dietzschold B., Wunner W. H., Osterhaus E. 1989; Characterization of a new virus-neutralizing epitope that denotes a sequential determinant on the rabies virus glycoprotein. Journal of General Virology 70:291–298
    [Google Scholar]
  6. Dietzschold B., Gore M., Casali P., Ueki Y., Rupprecht C. E., Notkins A. L., Koprowski H. 1990a; Biological characterization of human monoclonal antibodies to rabies virus. Journal of Virology 64:3087–3090
    [Google Scholar]
  7. Dietzschold B., Gore M., Marchadier D., Niu H. S., Bunschoten H. M., Otvos L. Jr, Wunner W. H., Ertl H. C. J., Osterhaus A. D. M. E., Koprowski H. 1990b; Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies glycoprotein and its possible use in a synthetic vaccine. Journal of Virology 64:3804–3809
    [Google Scholar]
  8. Ito H., Sukada Y., Mureata K., Kimura A. 1983; Transformation of intact yeast cells treated with alkali cations. Journal of Bacteriology 153:163–168
    [Google Scholar]
  9. Klepfer S. R., Debouck C., Uffelman J., Jacobs P., Bollen A., Jones E. V. 1993; Characterization of rabies glycoprotein expressed in yeast. Archives of Virology 128:269–286
    [Google Scholar]
  10. Lafon M., Wiktor T., MacFarlan R. I. 1983; Antigenic sites on the CVS rabies virus glycoprotein: analysis with monoclonal antibodies. Journal of General Virology 64:843–851
    [Google Scholar]
  11. Madaule P., Gairin J. E., Benichou S., Rossier J. 1991; A peptide library expressed in yeast reveals new major epitopes from human immunodeficiency virus type 1. FEMS Microbiology and Immunology 76:99–108
    [Google Scholar]
  12. Mink M. A., Benichou S., Madaule P., Tiollais P., Prince A. M., Inchauspe G. 1994; Characterization and mapping of a B-cell immunogenic domain in hepatitis C virus E2 glycoprotein using a yeast peptide library. Virology 200:246–255
    [Google Scholar]
  13. Miyajima A., Bond M. W., Otsu K., Arai K., Arai N. 1985; Secretion of mature mouse interleukin-2 by Saccharomyces cerevisiae: use of a general secretion vector containing promoter and leader sequences of the mating pheromone α-factor. Gene 37:155–161
    [Google Scholar]
  14. Muller G. M., Shapira M., Arnon R. 1982; Anti-influenza response achieved by immunization with synthetic conjugate. Proceedings of the National Academy of Sciences, USA 79:569–573
    [Google Scholar]
  15. Noraz N., Benichou S., Madaule P., Tiollais P., Vernant J. C., Desgranges C. 1993; Expression of HTLV-I Env and Tax recombinant peptides in yeast: identification of immunogenic domains. Virology 193:80–88
    [Google Scholar]
  16. Parry N. R., Barnett P. V., Ouldridge E. J., Rowlands D. J., Brown F. 1989; Neutralizing epitopes of type O foot-and-mouth disease virus. II Mapping three conformational sites with synthetic peptide reagents. Journal of General Virology 70:1493–1503
    [Google Scholar]
  17. Parry N., Fox G., Rowlands D., Brown F., Fry E., Acharya R., Logan D., Stuart D. 1990; Structural and serological evidence for a novel mechanism of antigenic variation in foot-and- mouth disease virus. Nature 347:569–572
    [Google Scholar]
  18. Préhaud C., Coulon P., Lafay F., Thiers C., Flamand A. 1988; Antigenic site II of the rabies virus glycoprotein: structure and role in viral virulence. Journal of Virology 62:1–7
    [Google Scholar]
  19. Raux FL., Coulon P., Lafay F., Flamand A. 1995; Monoclonal antibodies which recognize the acidic configuration of the rabies glycoprotein at the surface of the virion can be neutralizing. Virology 210:400–408
    [Google Scholar]
  20. Rini J. M., Stanfield R. L., Stura E. A., Salinas P. A., Profy A. T., Wilson I. A. 1993; Crystal structure of human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen. Proceedings of the National Academy of Sciences, USA 90:6325–6329
    [Google Scholar]
  21. Sanger F., Nicklen S., Coulson A. R. 1977; DNA sequencing with chain-terminating inhibitors. Proceedings of the National Academy of Sciences, USA 74:5463–5467
    [Google Scholar]
  22. Seif I., Coulon P., Rollin P. E., Flamand A. 1985; Rabies virulence: effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein. Journal of Virology 53:926–934
    [Google Scholar]
  23. Tormo J., Blaas D., Parry N. R., Rowlands D., Stuart D., Fita I. 1994; Crystal structure of a human rhinovirus neutralizing antibody complexed with a peptide derived from viral capsid protein VP2. EMBO Journal 13:2247–2256
    [Google Scholar]
  24. van der Heijden R. W. J., Langedijk J. P. M., Groen J., Uytdehaag M., Meloen F. G. C. R., Osterhaus A. D. M. E. 1993; Structural and functional studies on a unique linear neutralizing antigenic site (G5) of the rabies virus glycoprotein. Journal of General Virology 74:1539–1545
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-77-2-339
Loading
/content/journal/jgv/10.1099/0022-1317-77-2-339
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error